Authors

Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center

Latest:

Guideline Recommendations for CIN Prophylaxis

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

Hope S. Rugo, MD, Her UCSF Comprehensive Cancer Center

Hope S. Rugo, MD, UC

Hope S. Rugo, MD, UCSF

Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Therapeutic Advances in Prophylaxis Against CIN

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

Hope S. Rugo, MD, University of California

Hope S. Rugo, MD, University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Hope S. Rugo, MD, University of CaliforniaChristy A. Russell, MD, University of Southern California

Hospital

Hospital of the University of Pennsylvania

Hossein Borghaei, DO

Latest:

Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLC

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Hossein Borghaei, DO, Fox Chase Cancer Center

Latest:

SCLC: Rechallenging With Chemotherapy + I/O

Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.

Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health

Latest:

SCLC: Second-Line Options and Supportive Care

Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.

Hossein Borghaei, DO, MS, Fox Chase Cancer Center

Latest:

Emerging Treatments in SCLC: Impact of Targeted Therapy

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Howard A. Burris, III, MD

Latest:

Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBC

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Howard A. Liebman, MD, USC

Latest:

Future Directions in the Management of Immune Thrombocytopenia

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.

Howard A "Skip" Burris, III, MD

Latest:

Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.

Howard A. "Skip" Burris, III, MD, FASCO, FACP

Latest:

Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in Oncology

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.

Howard A. "Skip" Burris, MD

Latest:

Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBC

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Howard Cohen, RPh, MS, FASHP

Latest:

The Rise of Oral Oncolytics

Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services, Smilow Cancer Center, Yale New Haven Health, discusses the rise of oral oncolytics in the treatment landscape during the 2018 NCODA Fall Summit.